Publication for Cyp7a1 and Cyp8b1

Species Symbol Function* Entrez Gene ID* Other ID Gene
coexpression		 CoexViewer
mmu Cyp7a1 cytochrome P450, family 7, subfamily a, polypeptide 1 13122 [link]
mmu Cyp8b1 cytochrome P450, family 8, subfamily b, polypeptide 1 13124

Pubmed ID Priority Text
25651182 0.99 Cyp7a1 and/or Cyp8b1.
0.98 Cyp7a1, Cyp8b1) are regulated transcriptionally by the nuclear receptor FXR.
0.98 CYP7A1 is the rate-limiting enzyme while CYP8B1 regulates the synthesis of cholic acid and thus regulates the bile acid pool composition (Fig. 1A).
0.98 Cyp7a1 and Cyp8b1.
0.98 Cyp7a1, Cyp8b1 are indirect and are the result of the FXR-dependent increased expression of Shp and Fgf15/19 that encode proteins that function to inhibit transcription of specific genes.
0.98 Cyp8b1, but not Cyp7a1 mRNA levels were induced/de-repressed in the MafG+/- mouse liver (Fig. 5I).
0.97 Cyp7a1 expression have been extensively studied, much less is known about how FXR represses Cyp8b1 or whether FXR regulates the expression of other genes involved in the two bile acid synthetic pathways.
0.97 Cyp7a1 and Cyp8b1 in wild-type, but not Fxr-/-mice (Fig. 1B).
0.97 Cyp7a1 and/or Cyp8b1 mRNA levels are induced/de-repressed in cells or the livers of mice deficient for either Shp, Fgfr4/j3-klotho or MafG (Fig. 5) suggest that SHP, FGF15/19 and MAFG represent three complimentary pathways that control bile acid synthesis and composition.
0.96 Cyp8b1 as compared to Cyp7a1.
0.96 Cyp8b1 and Cyp7a1.
0.96 Cyp8b1 and/or Cyp7a1 remains to be established.
0.95 Cyp7a1 and Cyp8b1.
0.93 CYP7A1 and CYP8B1.
0.91 Cyp8b1, but not Cyp7a1, was de-repressed in mice after MafG silencing with the ASO treatment (Fig. 5G), thus recapitulating our in vitro findings in an in vivo setting.
0.89 Cyp7a1, the mechanisms involved in the repression of Cyp8b1, and thus cholic acid synthesis, are less well understood.
0.88 CYP7A1 and CYP8B1 expression in dose-dependent manner (Fig. 3G).
0.83 Cyp7a1 and Cyp8b1 are particularly responsive to end product feedback control.
0.80 Cyp8b1, unchanged Cyp7a1 and altered bile acid composition.
0.73 Cyp8b1 and Cyp7a1 (Fig. 1B).
0.54 Cyp7a1 or Cyp8b1 in vivo are at best very modest, while the effects of SHP overexpression on other bile acid synthetic genes or bile acid composition have not been reported.
24796972 0.99 CYP7A1 and CYP8B1 gene promoters (Fig 2, Pathway 1).
0.98 CYP7A1/CYP8B1 and bile acid synthesis via activating the ERK1/2, p38 and JNK1/2 pathways.
0.98 CYP7A1 and CYP8B1 gene transcription.
0.98 CYP7A1/CYP8B1 gene transcription.
0.98 CYP8B1 was markedly suppressed in liver of CYP7A1-tg mice (Fig 7B), consistent with the perturbed bile acid profiles as revealed in metabolomics (Fig. 6C).
0.97 CYP7A1-tg mice, these data show that in most of the tested tissues, 12alpha-hydroxylated bile acids (CA, TCA, DCA and TDCA) were decreased due to inhibition of CYP8B1 by increased bile acid pool in CYP7A1-tg mice.
0.96 CYP7A1-tg mice, enlarged bile acid pool inhibits CYP8B1 and reduces CA and DCA levels.
0.96 CYP7A1 is the rate-limiting enzyme and CYP8B1 catalyzes the synthesis of CA.
0.96 CYP7A1-tg mice, overexpressing CYP7A1 increases bile acid pool size and reduces cholic acid by inhibiting CYP8B1.
0.94 CYP7A1-tg mice, bile acid pool size increased 2.5-fold and CYP8B1 expression was abolished.
0.92 CYP7A1 activity and bile acid synthesis coupled to decreasing CYP8B1 and 12alpha-hydroxylated-bile acids may be a therapeutic strategy for treating diabetes and obesity.
23602448 0.99 Cyp7a1 and Cyp8b1, the rate-limiting enzymes in the synthesis of CDCA and CA (Figure 2A).
0.98 Cyp7a1 and Cyp8b1 mRNA levels, suggesting the presence of additional, SHP-independent mechanism(s) of repression.
0.97 Cyp7a1 and Cyp8b1 mRNA levels and increased, unregulated bile acid synthesis, and from the observation that treatment of intestinal Fxr-/- mice with specific FXR agonists fails to fully repress Cyp7a1 and Cyp8b1 expression.
0.97 Cyp7a1 and Cyp8b1, an increased bile acid pool size and decreased Fgf15 expression in enterocytes.
0.92 Cyp7a1 and Cyp8b1 involves at least two distinct mechanisms.
22467244 0.98 CYP7A1/Cyp7a1 and CYP8B1/Cyp8b1.
0.98 CYP7A1/Cyp7a1 and CYP8b1/Cyp8b1.
0.98 Cyp8b1 mRNA levels were increased upon cholestyramine in both Fxr Liv KO and Int KO mice (Fig 1D), suggesting that Fxr in enterocytes suppresses both Cyp7a1 and Cyp8b1, but in hepatocytes, Fxr mainly suppresses Cyp8b1.
0.98 Cyp7a1 and Cyp8b1 gene expression in the liver.
0.98 Cyp7a1 and Cyp8b1 gene expression.
0.98 Cyp7a1 or Cyp8b1 (Fig 4), indicating that Fgf15 and Shp may be the only two factors involved in mediating suppression of Cyp7a1 and Cyp8b1gene expression following Fxr activation.
0.98 Cyp7a1 and Cyp8b1 gene expression.
0.98 Cyp7a1 gene expression and both hepatic and intestinal Fxr activation is important in suppressing Cyp8b1 gene expression.
0.98 Cyp7a1 and Cyp8b1, Fgf15-activated JNK and ERK activation results in suppression of Cyp7a1 and Cyp8b1 expression, indicating that Fgf15 may switch the effects of MAPK on regulating Cyp7a1 and Cyp8b1 expression.
0.98 Cyp7a1 and Cyp8b1 genes, adding another layer of complexity in regulating bile-acid synthesis following MAPK activation.
0.98 Cyp7a1 and Cyp8b1, to mainly result in decreasing the expression of the Cyp8b1 gene, and to a minor extent, the Cyp7a1 gene.
0.98 Cyp7a1 and Cyp8b1 gene expression.
0.97 Cyp7a1 and Cyp8b1 gene expression.
0.97 Cyp7a1 in WT mice and FXR Liv KO mice and 3-fold induction of Cyp8b1 in all mice (Fig 1D), indicating increase in hepatic bile acids and/or Shp induction is not responsible for suppressing bile-acid synthesis.
0.97 Cyp8b1, but not Cyp7a1, gene expression
0.97 Cyp7a1 and Cyp8b1 gene expression
0.97 Cyp7a1 and Cyp8b1 gene expression after Fxr activation.
0.97 Cyp7a1 and Cyp8b1 gene expression after Fgf15 treatment, but also resulted in marked reduction of basal Cyp7a1 and Cyp8b1 gene expression, it is possible that JNK and ERK compensate each other's function.
0.97 Cyp7a1 and Cyp8b1 gene expression in mice (Fig 7).
0.97 Cyp7a1 and Cyp8b1 gene expression, as well as in maintaining basal expression of Cyp7a1 and Cyp8b1 gene.
0.97 Cyp7a1 and Cyp8b1.
0.97 Cyp7a1 and Cyp8b1 expression.
0.97 Cyp7a1 and Cyp8b1 gene expression after Fxr activation.
0.96 Cyp7a1 and Cyp8b1 gene expression.
0.96 Cyp7a1 and Cyp8b1 gene expression.
0.96 Cyp7a1 and Cyp8b1 gene
0.96 Cyp7a1 and Cyp8b1 gene expression.
0.96 Cyp7a1, but both are equally important in suppressing Cyp8b1, gene expression in mice.
0.96 Cyp7a1 and Cyp8b1 in mouse livers
0.95 Cyp7a1 and Cyp8b1 gene expression after Fxr activation.
0.95 Cyp7a1 gene expression, but instead, markedly reduced Cyp8b1 gene expression.
0.94 Cyp7a1 and Cyp8b1 gene expression, but the liver Fxr/Shp pathway was important for suppressing Cyp8b1 gene expression and had a minor role in suppressing Cyp7a1 gene expression.
0.94 Cyp7a1 but not Cyp8b1 mRNA levels was observed in these DKO mice (Fig 4).
0.94 Cyp7a1 and Cyp8b1 gene expression
0.93 Cyp7a1/CYP7A1 and Cyp8b1/CYP8B1 gene expression between mice and humans.
0.93 Cyp7a1, Cyp8b1 and Shp in the liver
0.92 Cyp7a1 and Cyp8b1 gene expression was determined in mice with cJun knock-down or Egr1 deletion.
0.92 Cyp7a1, Cyp8b1 and Shp in the liver, as well as on mRNA levels of Fgf15 in the intestine
0.91 Cyp7a1 and Cyp8b1, but did not prevent suppression of Cyp7a1 and Cyp8b1 by Fgf15 protein.
0.91 Cyp7a1 and Cyp8b1 mRNA levels and on activation of MAPK in the livers of WT mice
0.90 Cyp7a1 and Cyp8b1 gene expression, but Fxr in hepatocytes mainly suppressed Cyp8b1 gene expression
0.88 Cyp7a1 and Cyp8b1 in mice was determined.
0.87 Cyp7a1 gene expression, but Shp plays an equally important role as Fgf15 in suppressing Cyp8b1 gene expression.
0.86 Cyp7a1 and Cyp8b1 gene expression was established in mice.
0.84 Cyp7a1 and Cyp8b1 mRNA levels
0.83 Cyp8b1 gene expression were similar to those of the Cyp7a1 gene, except for an even smaller degree of suppression after Fgf15 treatment (Fig 6A).
0.77 Cyp7a1 and Cyp8b1 gene expression.
0.64 Cyp7a1 and Cyp8b1 requires Shp.
27359351 0.98 cholesterol 7alpha-hydroxylase (CYP7A1) and sterol 12alpha-hydroxylase (CYP8B1), which are inhibited by FXR.
0.98 Cyp7a1 and Cyp8b1 mRNA levels in wild-type mice but not in Fxr-/- mice (Figure 2A).
0.98 Cyp7a1 or Cyp8b1 was mitigated or abolished in L-Fxr-/- mice (Figure 2B) or I-Fxr-/- mice (Figure 2C), suggesting that OCA represses Cyp7a1 and Cyp8b1 expression via activation of hepatic and/or intestinal FXR.
0.98 CYP7A1 and CYP8B1 expression.
0.98 Cyp7a1 and Cyp8b1 expression and such a reduction was greatly attenuated in Shp-/- mice, indicating that activation of FXR represses Cyp7a1 and Cyp8b1 expression partly through induction of SHP.
0.98 CYP7A1 and CYP8B1 expression, OCA treatment reduced bile acid levels in the liver and gallbladder or intestine dependent on activation of hepatic or intestinal FXR, respectively (Figure 2E).
0.98 CYP7A1 and CYP8B1 expression and the bile acid pool size involves activation of hepatic and/or intestinal FXR and its downstream target SHP.
0.98 Cyp7a1 and Cyp8b1 or Cyp8b1 over-expression alone recapitulated TCA level to the normal level (Figure 6E).
0.98 CYP7A1 and CYP8B1 expression via activation of hepatic and intestinal FXR and partly through inducing SHP.
0.98 CYP8B1 or CYP7A1 plus CYP8B1 is sufficient to prevent OCA-induced inhibition of intestinal cholesterol absorption, demonstrating that activation of FXR inhibits intestinal cholesterol absorption via modulating bile acid metabolism.
0.98 CYP7A1 and CYP8B1 are key enzymes in the classic pathway of bile acid biosynthesis.
0.97 cholesterol 7alpha-hydroxylase (Cyp7a1) and sterol 12alpha-hydroxylase (Cyp8b1) partly through inducing small heterodimer partner (Shp), leading to reduced bile acid pool size and altered bile acid composition, with the alpha/beta-muricholic acid proportion in the bile increased by 2.6 fold and taurocholic acid (TCA) level reduced by 71%.
0.97 CYP8B1 or CYP7A1 plus CYP8B1.
0.97 Cyp7a1 and only partially inhibited Cyp8b1 (Figure 2C), which may explain why OCA treatment reduces fecal bile acid levels dependent on activation of intestinal FXR (Figure 1F).
0.97 Cyp7a1 and Cyp8b1 expression (Figure 4B).
0.97 CYP7A1 catalyzes the rate-limiting step whereas CYP8B1 determines the rate of CA biosynthesis (Figure 5A).
0.97 Cyp7a1 and/or Cyp8b1 increased bile acid levels in the intestine, liver and/or gallbladder as well as total bile acid levels in vehicle-treated mice (Figure S6A-D).
0.97 CYP8B1 alone or CYP7A1 plus CYP8B1, but not CYP7A1 alone, reverses OCA-induced changes in bile acid level (TCA), bile acid composition (TCA and alpha/beta-MCAs) and cholesterol absorption.
0.97 CYP8B1 alone or CYP7A1 plus CYP8B1 does not restore DCA/TDCA levels, suggesting that OCA inhibits cholesterol absorption through inhibition of CA/TCA synthesis and induction of alpha/beta-MCA levels.
0.96 Cyp7a1 or Cyp8b1 increased intestinal bile acid levels to a similar extent in OCA-treated mice (Figure 6A), Cyp8b1, but not Cyp7a1, over-expression was able to normalize cholesterol absorption (Figure 5B).
0.96 Cyp8b1 or Cyp7a1 plus Cyp8b1 over-expression (Figure 6E).
0.95 Cyp7a1 and Cyp8b1 (Figure 4F), suggesting that GW4064 functioned properly in vivo.
0.95 Cyp7a1 and Cyp8b1 expression, we asked whether recapitulation of hepatic Cyp7a1 and/or Cyp8b1 levels would prevent FXR-induced inhibition of cholesterol absorption.
0.95 Cyp7a1 and Cyp8b1 or Cyp8b1 over-expression alone completely recovered or increased bile acid levels in the intestine, liver and gall bladder as well as total bile acid levels in OCA-treated mice (Figure 6A-6D).
0.95 Cyp8b1 alone or Cyp7a1 plus Cyp8b1 but not by over-expression of Cyp7a1 alone (Figure 6F).
0.95 Cyp7a1-/- mice or Cyp8b1-/- mice have reduced intestinal cholesterol absorption and increased fecal sterol secretion.
0.94 Cyp8b1 or concurrent over-expression of Cyp7a1 and Cyp8b1 normalizes TCA level, bile acid composition and intestinal cholesterol absorption.
0.94 Cyp7a1 and Cyp8b1 or over-expression of Cyp8b1 alone, but not Cyp7a1 alone, recovered intestinal cholesterol absorption to the normal level in OCA-treated mice (Figure 5B).
0.92 CYP8B1 alone or CYP7A1 plus CYP8B1 prevents OCA from inhibiting intestinal cholesterol absorption
0.91 CYP8B1 alone or CYP7A1 plus CYP8B1 prevents OCA from altering TCA and MCA levels
0.89 CYP7A1 and CYP8B1 expression through activation of hepatic and/or intestinal FXR and partly through SHP
0.89 CYP8B1 or CYP7A1 plus CYP8B1 prevents FXR-induced increase in muricholic acid level and decrease in taurocholic acid level
0.89 CYP7A1 and CYP8B1 expression through activation of hepatic and/or intestinal FXR and partly through SHP
0.77 CYP7A1 and CYP8B1 prevents FXR-induced inhibition of intestinal cholesterol absorption, we analyzed bile acid pool size and bile acid composition.
25545350 0.98 Cyp7a1 and Cyp8b1, and the BA uptake transporter gene, Ntcp, and removes a gene-activation mark, tri-methylated histone H3 lysine-4, leading to gene repression.
0.98 Cyp7a1 and Cyp8b1, by recruiting repressive chromatin-modifying enzymes.
0.98 CYP7A1 and CYP8B1 by erasing a gene activation histone mark, H3K4-me3, and that this step is important for the following decreased H3K9/14 acetylation and increased H3K9 methylation.
0.98 Cyp7a1 and Cyp8b1 genes by BA.
0.98 Cyp7a1, Cyp8b1, and Ntcp promoters (Fig. 7A).
0.98 Cyp7a1 and Cyp8b1, and a BA uptake gene, Ntcp, and removes a gene activation histone mark, histone H3K4-me3, resulting in epigenomic repression of these genes.
0.98 Cyp7a1, Cyp8b1, and Ntcp, provides a molecular mechanism for the feedback inhibition of BA synthesis and uptake regulated by the FXR/SHP pathway.
0.98 CYP7A1 and CYP8B1 genes in a SHP-dependent manner and demethylates H3K4-me3, which is required for additional repressive histone modifications in HepG2 cells
0.97 Cyp7a1 and Cyp8b1 by recruitment of the histone-modifying enzymes, HDACs and G9a, we asked if FXR-induced LSD1, which removes a histone activation mark, contributes to SHP-mediated epigenomic repression.
0.97 Cyp7a1 and Cyp8b1, as well as a SHP-target BA uptake transporter gene, Ntcp, that plays a crucial role in regulating hepatic BA levels (Fig. 5A).
0.97 Cyp7a1 and Cyp8b1 in vitro and in vivo.
0.96 Cyp7a1, Cyp8b1, and Ntcp, and strikingly, the inhibition of Ntcp was largely reversed by downregulation of LSD1, while the inhibition of Cyp7a1 and Cyp8b1 was only partially reversed (Fig. 5D).
0.96 Cyp7a1 and Cyp8b1, as noted, respond similarly to BA overload when LSD1 is downregulated, but because of the elevated basal levels, are still expressed at higher levels than in the BA overloaded control mice.
0.96 Cyp7a1, Cyp8b1, and Ntcp promoters.
0.94 CYP7A1 and CYP8B1 promoters as detected by ChIP.
0.80 CYP7A1 and CYP8B1.
25175738 0.98 Cyp7a1, Cyp8b1, and Akr1d1, which are involved in bile acid synthesis.
0.98 Cyp7a1 and Cyp8b1.
0.98 CYP7A1 and CYP8B1.
0.98 Cyp7a1, Cyp8b1, and Akr1d1, which are involved in bile acid biosynthesis or metabolism.
0.98 Cyp7a1, Cyp8b1, and Akr1d1, all of which control bile acid synthesis.
0.98 Cyp7a1 and Cyp8b1 expression.
0.98 Cyp7a1 and Cyp8b1 expression.
0.98 Cyp7a1 as well as Cyp8b1 to limit the synthesis of bile acids.
0.98 Cyp7a1 and Cyp8b1.
0.98 CYP7A1, all-trans RA also reduced the gene and protein expression of CYP8B1, which is crucial for CA synthesis.
0.97 CYP7A1 and CYP8B1, which in turn reduces bile acid synthesis and affects lipid absorption in the gastrointestinal tract.
0.95 CYP7A1 and CYP8B1) and the acidic pathways (CYP27A1 and CYP7B1).
0.95 Cyp7a1, and Cyp8b1.
0.94 CYP7A1 and CYP8B1, but increased SHP protein level (Fig. 5), which was consistent with gene expression data shown in figure 2.
0.88 CYP7A1 and CYP8B1 levels were reduced, but SHP level was increased by all-trans RA treatment.
27412403 0.98 Cyp7a1 and Cyp8b1 (ref.), and the BA import transporter gene, Ntcp, by recruiting repressive histone-modifying enzymes, such as HDACs and LSD1 (refs).
0.98 Cyp7a1 and Cyp8b1, and a well-known SHP-interacting nuclear receptor.
0.98 Cyp7a1 and Cyp8b1 in hepatocytes expressing SHP-WT, but these effects were attenuated by the K68R mutation (Fig. 4c).
0.98 Cyp7a1 and Cyp8b1, and a BA import transporter, Ntcp (Supplementary Fig. 7).
0.98 Cyp7a1 and Cyp8b1 was significantly increased (Fig. 6c), suggesting that SUMOylation of SHP plays an important role in mediating FGF15 inhibition of BA synthetic genes.
0.98 Cyp7a1 and Cyp8b1 in hepatocytes from SHP-KO mice expressing SHP-WT, but the FGF19-mediated inhibition of these genes was blunted with the K68R mutation (Fig. 6e).
0.98 Cyp8b1 promoter and represses expression of this gene, but MAFG does not directly repress Cyp7a1 (ref.).
0.97 Cyp7a1 was decreased, mRNA levels of the BA synthetic gene, Cyp8b1, BA import genes, and inflammatory genes were increased (Fig. 8b), and pathological changes in the liver were evident with increased liver necrosis and infiltration of macrophages (Fig. 8c).
0.97 Cyp7a1 and Cyp8b1 mRNA levels were increased in mice expressing the K68R-SHP mutant in normal physiological conditions, but these two genes were differentially regulated upon ANIT or chronic CA feeding.
0.96 CYP7A1 (Fig. 2g) and CYP8B1 (Supplementary Fig. 3b).
0.96 Cyp8b1, which regulates BA hydrophobicity, were highly increased, while those of Cyp7a1 and Cyp7b1 were decreased in the mice expressing the K68R mutant (Fig. 8g).
0.96 Cyp7a1 and Cyp8b1 genes was upregulated.
29259301 0.98 Cyp7a1 and Cyp8b1 mRNA levels were induced by ~1.8 fold (Fig. 6A), which was accompanied by a 99% reduction in fibroblast growth factor 15 (Fgf15) in the intestine (Fig. 6A).
0.98 CYP7A1 and CYP8B1 expression.
0.97 Cyp7a1 and Cyp8b1 expression.
0.97 Cyp7a1 and Cyp8b1 were elevated and intestinal Fgf15 level was repressed in DKO mice compared with control littermates (Fig. 6G).
0.97 Cyp7a1 and Cyp8b1 are induced in Ces1/Ces1g -/- mice likely as a result of inhibition of intestinal Fgf15.
0.97 Cyp7a1 and Cyp8b1 are key enzymes in cholesterol catabolism in the liver, the induction of Cyp7a1 and Cyp8b1 may also contribute to the atheroprotective effect of Ces1/Ces1g inactivation.
0.96 Cyp7a1 and Cyp8b1 may contribute to hypocholesterolemia in Ces1/Ces1g -/- mice.
0.95 cholesterol 7alpha-hydroxylase (CYP7A1) and sterol 12alpha-hydroxylase (CYP8B1) or secreted directly to the bile.
0.94 cholesterol 7alpha-hydroxylase and sterol 12alpha-hydroxylase expression.
0.93 CYP7A1 and CYP8B1 expression and bile acid synthesis
29404434 0.98 Cyp7a1 and Cyp8b1.2 Measured mRNA levels of CREBH showed significant induction of this gene only in the Ctrl-Hum and Alc-Hum mice (Fig. 5).
0.96 Cyp7a1 and Cyp8b1 was significantly up-regulated in Alc-Hum and Ctrl-Hum mice but not in Cirr-Hum, GF, or GF mice fed 0.04% DCA (Fig. 2A,B).
0.95 Cyp7a1 and Cyp8b1 are rate limiting for the synthesis of cholic acid.
0.95 Cyp7a1 and Cyp8b1.2 Cannabinoid receptor type 1 (CB1R) has been reported to activate CREBH by up-regulating Cyp7a1, Cyp8b1, and BA synthesis.2 CB1R is normally activated by endocannabinoids (anandamide and 2-arachidonoyl glycerol), but recent studies report it can be activated by ethanol.2, 25 Therefore, these data suggest that the gut microbiota from Ctrl-Hum and Alc-Hum mice may be producing a compound(s) that activates hepatic CB1R.
0.93 Cyp7a1 and sterol 12alpha-hydroxylase (Cyp8b1) messenger RNA (mRNA) levels were significantly induced in the Alc-Hum and Ctrl-Hum mice but not in the Cirr-Hum mice or GF mice.
0.91 Cyp7a1 and Cyp8b1.
0.90 Cyp7a1 and Cyp8b1.
0.86 Cyp7A1 and Cyp8B1 were highly up-regulated, we wanted to determine if intestinal or liver FGF-15 mRNA or hepatic SHP mRNA was induced.
0.76 CYP7A1 AND CYP8B1 BY FGF-15 AND SHP
0.75 Cyp7a1 and Cyp8b1 expression was highest in the Alc-Hum and Ctrl-Hum groups compared to GF, DCA, and Cirr-Hum mice.
20531290 0.98 Cyp7A1 and Cyp8B1 mRNA levels.
0.98 Cyp7A1 and Cyp8B1 are key enzymes in bile acid synthesis, Shp is the second messenger of FXR and Dbp, Rev-erbalpha and E4bp4 are involved in maintaining the circadian rhythm of Cyp7A1 expression.
0.95 Cyp7A1 and Cyp8B1 expression patterns.
0.95 Cyp7A1 and Cyp8B1 expression.
0.95 Cyp7A1, whereas Cyp8B1 repression was more sensitive to loss of hepatic FXR.
0.94 Cyp7A1, not reaching statistical significance in WT mice, and of Cyp8B1 in both genotypes.
0.94 Cyp7A1 and Cyp8B1 expression patterns.
0.89 Cyp7A1 and Cyp8B1 expression in control as well as in iFXR-KO mice, although the downregulation of Cyp7A1 did not reach statistical significance in WT mice.
0.83 Cyp7A1 was more strongly affected by disruption of intestinal FXR, whereas repression of Cyp8B1 was more sensitive to loss of hepatic FXR.
26501563 0.98 Cyp7a1 and Cyp8b1 expression.
0.98 Cyp7a1 and Cyp8b1 (Cell Metab 2015;21:298-310).
0.98 Cyp8b1 expression without alteration of Cyp7a1 levels, changing the composition of bile acid pool (Mol Endocrinol 2008;22:1345-1356; Mol Cell Biol 2007;27:8330-8339).
0.97 Cyp8b1, but not Cyp7a1, in the liver.
0.95 Cyp8b1, Cyp7b1, and Cyp27a1, but not Cyp7a1.
0.90 CYP7A1 regulation was extensively studied (Mol Cell 2000;6:517-526; Hepatology 2009;49:297-305; J Biol Chem 2012;287:41334-41341), little information was available as to the mechanism of how FXR signaling regulates the alternative pathway or if the repression of CYP8B1 is responsible for cholic acid synthesis.
0.89 Cyp8b1 and other genes involved in bile acid synthesis, but not in the 100-kb upstream of Cyp7a1.
0.81 Cyp8b1, Cyp27a1, Cyp7b1, Acox2, Akr1d1, Akr1c14, Ntcp, Hsd17b4, and Scp2, but not Cyp7a1.
29188025 0.98 CYP7A1 and CYP8B1 genes.
0.98 CYP7A1/CYP8B1 activity.
0.98 CYP7A1 and CYP8B1 genes ( Figure 1).
0.98 CYP7A1 and CYP8B1 gene transcription ( Figure 1).
0.98 Cyp7a1 and Cyp8b1 gene transcription ( Figure 1).
0.97 cholesterol 7alpha-hydroxylase (CYP7A1) to synthesize cholic acid (CA), which requires sterol 12alpha-hydroxylase (CYP8B1), and chenodeoxycholic acid (CDCA).
0.97 CYP7A1 and CYP8B1 gene transcription.
0.97 Cyp8b1 -/- mice, and antibiotic-treated mice share common phenotypes; that is, all have increased CYP7A1 expression and enlarged bile acid pool with reduced TCA and increased T-MCA compared to wild type mice, and these mice are resistant from diet-induced obesity (DIO) .
29404516 0.98 Cyp7a1 and Cyp8b1 gene transcription.
0.98 Cyp7a1 and Cyp8b1 expression in hepatocytes by activating the c-Jun N-terminal kinase pathway.26, 27
0.97 Cholesterol 7alpha-hydroxylase (Cyp7a1) is the rate-limiting enzyme in the classic bile acid synthesis pathway, which plays a critical role in maintaining cholesterol and bile acid homeostasis,6 while sterol 12alpha-hydroxylase (Cyp8b1) is involved in cholic acid (CA) synthesis.
0.97 Cyp8b1, Cyp7b1, and Cyp27a1 mRNA levels was induced in isocaloric pair-fed control Cyp7a1 -/- mice (Fig. 2A).
0.97 Cyp7a1-Tg mice had significantly reduced mouse Cyp7a1 and Cyp8b1 mRNA levels compared to wild-type mice (Fig. 5C) due to activation of FXR by CDCA.17 Alcohol feeding reduced Cyp7b1 and Cyp27a1 mRNA levels in both wild-type and Cyp7a1-Tg mice (Fig. 5C).
0.96 Cyp7a1, Cyp8b1, and Cyp7b1 mRNA levels in wild-type mice and reduced Cyp8b1 mRNA levels in female Cyp7a1 -/- mice (Fig. 2A).
0.90 Cyp7a1 protein in Cyp7a1-Tg mice (Fig. 5D) as well as Cyp8b1 and Cyp7b1 protein, while Cyp27a1 protein levels were unchanged (Fig. 5E).
0.83 Cyp8b1 were unchanged, while protein levels of Cyp7b1 were decreased by ethanol feeding in wild-type mice and increased by ethanol feeding in Cyp7a1 -/- mice.
30060524 0.98 Cyp7a1, Cyp8b1), and energy homeostasis (Aldoc, Slc2a5).
0.98 CYP7A1 and CYP8B1.
0.98 CYP7A1 and CYP8B1 in HepG2 cells, because ligand-activated PXR interacts with PGC1alpha.
0.98 CYP7A1 and CYP8B1 expression levels, which occurs during the progression of this disease.
0.97 Cyp7a1 and Cyp8b1 were significantly suppressed by MK-4 treatment in hPXR mice, but not in WT mice.
0.96 CYP7A1 and CYP8B1 mRNA in HepG2 cells.
0.95 Cyp7a1 and Cyp8b1 were also significantly suppressed by the treatment with lower doses of MK-4 in hPXR mice, but not in WT mice (Figure 5A).
0.69 Cyp8b1 mRNA level (cytochrome P450, family 8, subfamily b, polypeptide 1) was not significantly altered by Rif treatment either (Figure 4A, Upper).
22197325 0.98 Cyp8b1, encoding the 12alpha-hydroxylase enzyme, was sharply downregulated in all tested conditions (Figure 3B-D), as were enzymes involved in other steps of BA metabolism, including Cyp7a1, Cyp27a1, Cyp7b1 (Figure 3B-D, Table S2).
0.98 Cyp7a1 and Cyp8b1 by inducing the nuclear co-repressor Shp (encoded by Nr0b2), which inhibits transcription factor Lrh-1 (encoded by Nr5a2).
0.98 Cyp8b1 with simultaneous induction of Cyp7a1, the rate-limiting enzyme of BA synthesis.
0.96 Cyp8b1, Cyp7a1, and Cyp27a1 compared to control littermates, and the reduction in Cyp8b1 tended to be exacerbated by triple knockout, compared to single FoxO1 knockout (Figure 4A).
0.94 Cyp8b1 is compounded by the failure to fully induce Cyp7a1, resulting in the characteristic BA profile of L-FoxO1 mice.
0.86 Cyp7a1 and Cyp8b1.
0.84 Cyp7a1 and Cyp8b1 (Figure 5A).
25489402 0.98 Cholesterol 7-alpha-hydroxylase is the rate-limiting enzyme for cholesterol degradation to bile acid, and regulates CYP8b1.
0.96 CYP7a1 and CYP8b1.
0.96 CYP7a1 and CYP8b1 in mice fed a hypercholesterolemic diet.
0.95 cholesterol 7-alpha-hydroxylase (CYP7a1), and sterol 12-alpha-hydroxylase (CYP8b1) was increased in mice fed red rice.
0.95 CYP7a1 and CYP8b1 in mice fed a hypercholesterolemic diet.
0.95 CYP7a1 and CYP8b1 was significantly increased in RR-HC, BR-HC, and NC compared with HC (Fig. 3).
0.95 CYP7a1 and CYP8b1 was significantly increased in mice fed red and brown rice.
27709014 0.98 CYP7A1, which is the rate-limiting enzyme in the classic pathway of bile acid synthesis, and CYP8B1, which is required for the synthesis of cholic acid.
0.98 Cyp7a1 and Cyp8b1 transcription.
0.97 CYP7A1 is the rate-limiting enzyme in the classic bile acid synthesis pathway, and CYP8B1 is required for synthesis of cholic acid.
0.96 CYP7A1 and CYP8B1, was only reduced at young ages in Fxr-null mice, also suggesting developmental stage-specific effect of FXR (Fig. 5C). And the result indicated that the induction of CYP7A1 at day 60 was mainly due to failed suppression from the FXR intestinal pathway.
0.93 CYP7A1 and CYP8B1 are as follows.
0.84 CYP7A1 and CYP8B1 were under the same FXR regulatory pathway, Cyp8b1 mRNA level was not significantly altered in Fxr-null mice (Fig. 5B).
0.58 Cyp7a1, (B) Cyp8b1 and (C) Shp during liver development.
28210689 0.98 cholesterol 7alpha-hydroxylase and sterol 12alpha-hydroxylase expression.
0.98 Cyp7a1 and Cyp8b1 genes were dramatically reduced, whereas expression of LDL receptor and sterol response element-binding protein 2 (SREBP-2) genes were significantly up-regulated.
0.98 Cyp7a1 and Cyp8b1 gene transcription and the reduction of cholesterol catabolism.
0.98 Cyp7a1 and Cyp8b1 genes.
0.97 Cyp7a1 and Cyp8b1, leading to increased biliary cholesterol saturation and hydrophobicity indices.
0.97 Cyp7a1 in regulating the pool size and of Cyp8b1 in controlling bile acid profiles, it is possible that these genes may have acquired more sophisticated expression control mechanisms to allow for a greater flexibility in the precise regulation of bile acid homeostasis in response to alterations in nutrition and growth conditions.
0.95 Cyp7a1 and Cyp8b1 gene expression remain unknown.
29498526 0.98 Cyp7a1 and Cyp8b1 involved in BA synthesis.
0.98 Cyp7a1 and Cyp8b1 genes.
0.97 Cyp7a1, Cyp8b1, Mrp3, Cyp3a11, Cyp2b10, Ugt1a2, and Ugt1a5 genes and showed cross-talk between basal PPARalpha and potentially adaptive pathways.
0.97 Cyp7a1, Cyp8b1, Oatp1, and Oatp2, were all down-regulated in the cholestatic groups.
0.89 CYP7A1 and CYP8B1 proteins were decreased in the two cholestatic groups, but CYP7A1 in the WT-C group was also significantly lower than that of the KO-C group.
0.80 Cyp7a1 and Cyp8b1 mRNA levels in the WT-A groups were decreased by 97% and 94% compared with the WT-C group, respectively (P < 0.05).
0.68 Cyp7a1 and Cyp8b1 in the two cholestatic groups was mainly attributed to strong adaptation, considering their correlation with the TBA levels.
21801835 0.98 CYP7A1, encoding the rate-limiting enzyme in the classic (neutral) bile acid synthesis pathway, and CYP8B1, which is required for synthesis of CA.
0.98 CYP7A1 and CYP8B1.
0.97 Cyp7a1 and Cyp8b1 expression and activity and a corresponding increase in the bile acid pool size, and in SHP transgenic mice, which have reduced expression of Cyp7a1 and a smaller hepatic bile acid pool size.
0.96 CYP7A1, FXR-mediated repression of CYP8B1 was more dependent on the presence of FXR in liver (through SHP) and less dependent on its presence in intestine (FGF15).
0.95 CYP7A1 mRNA levels without affecting CYP8B1 expression.
0.75 CYP7A1 also explains observed differences in feedback repression between CYP7A1 and CYP8B1.
26122550 0.98 CYP8B1 and cholic acid in bile acid pool, but not CYP7A1 suggesting that MAFG may regulate bile acid composition (Fig. 1).
0.98 CYP7A1 and CYP8B1 gene transcription by an indirect mechanism (Pathway 2, Fig. 1).
0.98 CYP7A1/CYP8B1 gene (Pathway 2).
0.98 CYP7A1/CYP8B1 gene transcription (Pathway 3).
0.97 CYP7A1 and CYP8B1 gene transcription and bile acid synthesis.
0.97 CYP7A1, CYP8B1, CYP27A1 and CYP7B1 in bile acid synthesis, and to induce bile acid:CoA synthase in bile acid conjugation and bile acid: amino acid transferase in bile acid transport.
27609522 0.98 Cyp7a1 and Cyp8b1).
0.98 Cyp7a1 and Cyp8b1 and induce Shp and Fgf15 mRNA is mitigated by deletion of Fxr in all tissues of mice.
0.97 Cyp7a1, Cyp8b1), conjugating enzymes (Bal, Baat) and transporters in the ileum (Asbt, Ostalpha/beta) and liver (Ntcp, Bsep, Ostbeta).
0.97 Cyp7a1, and sterol 12alpha-hydroxylase, Cyp8b1) or alternative (key enzyme steroid 27-hydroxylase, Cyp27a1) pathways and released into the intestinal lumen to promote the absorbance of lipids and lipid-soluble vitamins.
0.97 Cyp7a1 and Cyp8b1 mRNA levels in an Fxr dependent manner, and not in Fxr-null mice.
0.91 Cyp7a1 expression, and a 55% elevation in Cyp8b1, was also observed in pregnant mice.
27929393 0.98 CYP7A1/B1, while ABCG5/8, CYP7A1, and CYP8B1 regulate bile acid synthesis from cholesterol.
0.98 CYP7A1, and CYP8B1.
0.96 Cyp7A1 and Cyp8B1 mRNA.
0.95 cholesterol 7 alpha-hydroxylase (CYP7A1), and sterol 12-alpha-hydroxylase (CYP8B1), as well as oxidative stress markers, including superoxide dismutase 1 (SOD1), superoxide dismutase 2 (SOD2), glutathione peroxidase (GPX), and catalase, were also regulated by XB supplementation.
0.91 CYP7A1 and CYP8B1, while XB supplementation significantly upregulated these enzymes.
0.87 CYP7A1 (Cyp71a) and CYP8B1 (Cyp8b1) were lower by 31% and 30% respectively, in the DB group compared with the Ctrl group (p < 0.05 for both), and the levels of these genes in the XB 5 group increased by 48% and 38%, respectively, compared to the DB group (p < 0.05 for both).
29104811 0.98 Cyp7a1 and Cyp8b1 gene promoters.
0.98 Cyp7a1 and Cyp8b1 gene transcription.
0.98 CYP7A1 and CYP8B1 gene transcription.
0.97 CYP7A1 and the branch enzyme for cholic acid synthesis CYP8B1 (Fig. 3).
0.97 CYP7A1, CYP8B1, and CYP27A1 to reduce bile acid synthesis and induces multidrug resistant protein 3, UDP-glucuronosyl transferase family 2B4, sulfur transferase family 2A1, and detoxification of bile acids.
0.94 CYP7A1, CYP8B1, and bile acid synthesis.
31039009 0.98 CYP7A1 and CYP8B1, suppressing bile acid production.
0.98 CYP7A1/CYP8B1 pathway was affected by Myd88 deletion.
0.97 CYP7A1 and CYP8B1 in parallel with p-JNK, was lower in Myd88 Hep mice fed with HFD compared with WT mice.
0.94 Cyp8b1 is strongly overexpressed in Myd88 Hep-HFD mice, it might indicate that p-ERK is more potent at inhibiting it than Cyp7a1.
0.92 Cyp7a1 and Cyp8b1 mRNA, we wondered whether the enterohepatic feedback loop controlling bile acid synthesis could be altered in Myd88 Hep compared with WT mice.
0.80 Cyp7a1 and Cyp8b1 Is Impaired in Myd88 Hep Mice
31102537 0.98 Cyp8b1 by H4 acetylation, whereas hepatic Cyp7a1 expression is regulated by blood glucose levels.
0.97 Cyp8b1, but not the repression of Cyp7a1, in liver-specific GSD Ia and GSD Ib mice.
0.97 CYP7A1 expression is partly controlled by circulating glucose levels, whereas intrahepatic glucose (G6P) appears to be the major regulator of CYP8B1 expression.
0.96 Cyp8b1 expression, whereas Cyp7a1 and Cyp27a1 expression were reduced and Cyp7b1 and Cyp2c70 expression remained unchanged (Fig. 1A).
0.96 CYP8B1, we found that hepatic levels of CYP7A1 protein, the supposedly rate-controlling enzyme in bile acid synthesis, as well as the plasma concentrations of its product C4 correlated with circulating glucose levels.
0.92 Cyp8b1 mRNA levels were also strongly elevated whereas expression of Cyp7a1, Cyp27a1, Cyp7b1, and Cyp2c70 was significantly lower as compared to L-G6pc+/+ littermates (Fig. 1C).
24033844 0.98 CYP7A1 and CYP8B1 expression.
0.97 CYP7A1 and CYP8B1 mRNA via FXR and SHP.
0.97 CYP7A1 and CYP8B1 mRNA expression was increased in Shp-/- mice (5.90+-0.86, p=0.0002, 2.23+-0.20, p=0.0003, respectively, Fig. 4 A).
0.96 CYP7A1 gene Hepatic CYP7A1 and CYP8B1 mRNA levels were suppressed in FGF19-treated mice (0.06+-0.03, p=0.0001, 0.50+-0.13, p=0.005) compared to vehicle-injected control mice (Fig. 5 A).
0.94 CYP7A1 and CYP8B1 mRNA (0.06+-0.03, p=0.10 and 0.07+-0.03, p=0.03 respectively) compared to control mice (Fig. 3 A).
24981838 0.98 Cyp7a1, Cyp8b1 and Cyp27a1, in Shp2hep-/- livers (Figure 5A).
0.98 Cyp7a1 and Cyp8b1 markedly increased in WT mice after cholestyramine treatment (Figure 5E).
0.97 Cyp7a1 and Cyp8b1 expression in WT controls (Figures 6B, 6C and S4B).
0.97 Cyp7a1 and Cyp8b1 expression in WT livers, but this response was diminished in Shp2hep-/- livers (Figure 6).
0.94 Cyp7a1 and Cyp8b1 is likely controlled by common and distinct pathways.
28249273 0.98 CYP7A1 and CYP8B1 gene expression.
0.98 CYP7A1 and CYP8B1 gene transcription.
0.98 CYP7A1 and CYP8B1 gene transcription.
0.97 CYP7A1 and CYP8B1 gene transcription.
0.93 CYP7A1 expression rapidly increases after feeding and decreases after fasting, while CYP8B1 is stimulated by fasting and decreased by feeding.
30105069 0.98 Cyp7a1 and Cyp8b1 which were two rate-limit enzymes of bile acids biosynthesis.
0.96 Cyp7a1, Cyp8b1, Fxr, Lrh1, Jnk1/2, and Erk1/2 were upregulated by gypenosides.
0.96 Cyp7a1 and Cyp8b1, Genes Encoding Enzymes Limiting Rate of Bile Acids Biosynthesis
0.95 Cyp7a1 and Cyp8b1 by times.
0.56 Cyp7a1, Cyp8b1, Fxr, Shp, Lrh1, Hnf4alpha, Jnk1/2, Erk1/2, and Fgfr4, as well as intestinal Fxr and Fgf15.
21071704 0.98 cholesterol 7alpha-hydroxylase (CYP7A1) and sterol 12alpha-hydroxylase (CYP8B1), two key enzymes that control bile acid biosynthesis.
0.98 Cyp7a1, Cyp8b1), cholesterol esterification (Acat2, Lcat), and cholesterol uptake (Ldlr, SR-BI) were all significantly reduced in Hnf4alpha-deficient mice (Figure 2A).
0.95 Cyp7a1 or Cyp8b1 has been shown to reduce intestinal cholesterol absorption.
0.94 Cyp8b1, SR-BI and Apoc2 (Figure 5A), but did not affect the mRNA levels of Hmgcr, Hmgcs, Cyp7a1, Abca1, Abcg5, Abcg8, Apoa1, Acat2, Lcat, or Srebp-1c (Figure 5A).
21437243 0.98 Cyp7a1 and Cyp8b1 encoding cholesterol 7alpha-hydroxylase and Sterol 12 alpha-hydroxylase respectively, two key enzymes for hepatic BA synthesis.
0.98 Cyp7a1 and Cyp8b1.
0.98 Cyp7a1 and Cyp8b1, shifting BA synthesis towards production of CDCA or its derivatives.
0.95 Cyp7a1 and Cyp8b1 did not differ between FGF19 and FGF19v (Fig. 3F).
22609541 0.98 Cyp7a1 and Cyp8b1 expression; deficiency of either pathway alone and minimal effect on FGF15 suppression of these genes.
0.97 CYP7A1 and CYP8B1 are two hepatic enzymes catalyzing formation of the primary bile acids CA and CDCA from cholesterol.
0.97 CYP7A1 and CYP8B1 genes.
0.93 CYP7A1 and CYP8B1 expression via the hepatic FXR-SHP and intestinal FGF15/19 pathways.
23536474 0.98 Cyp7a1-tg mice, endogenous mouse CYP7A1 and sterol 12alpha-hydroxylase (CYP8B1) mRNA levels were decreased as the result of increased bile acid feedback (Table 2).
0.98 CYP7A1 and CYP8B1 and Na+-dependent taurocholate co-transport peptide (NTCP), the basolateral bile acid uptake transporter (Fig 3A).
0.97 CYP7A1, CYP8B1 and ABCA1 (Fig 4D, E and F).
0.93 CYP7A1 and CYP8B1, and ABCA1 (positive control).
25506828 0.98 Cyp7a1 and Cyp8b1, thereby inhibiting CA production.
0.97 Cyp7a1 (19% reduction) and Cyp8b1 (17% reduction), indicating that FXRalpha2 transrepressed both Cyp7a1 and Cyp8b1 more strongly than FXRalpha4.
0.97 Cyp7a1 and Cyp8b1 expression through a SHP/LRH1- and HNF-4alpha-dependent pathway.
0.95 Cyp7a1- as well as Cyp8b1-knock-out mice, in which CA was largely replaced by MCA, fractional cholesterol absorption from the intestine was decreased while the intestinal cholesterol synthesis was induced as a rescue mechanism.
29339445 0.98 CYP7A1-dependent suppression by FXR is mediated by two mechanisms: (1) in the liver, FXR induces the expression of the small heterodimer partner (SHP), which in turn inhibits CYP7A1 expression; (2) in the gut, FXR increases the levels of circulating fibroblast growth factor 19 (FGF19; FGF15 in mice), which reduces the expression of CYP7A1 and cytochrome P450 12a-hydroxylase B1 (CYP8B1), leading to inhibition of BA synthesis (Fig. 1).
0.98 CYP7A1 and CYP8B1 are mediated by hepatic FGF4/betaKlotho receptor (FGFR4/betaKlotho; Fig. 1).
0.97 Cyp7A1 and Cyp8B1.
0.97 Cyp7a1 and Cyp8b1 and suppression of Fgf15 expression in the ileum.
32116693 0.98 CYP7A1 and CYP8B1to limit the synthesis of bile acids.
0.98 CYP7A1 and CYP8B1 induced by liver homolog-1 (LRH-1)-induced gene transcription of CYP7A1 and CYP8B1.
0.98 CYP7A1 and CYP8B1 gene expression.
0.96 CYP7A1) and sterol 12alpha-hydroxylase (CYP8B1) are the rate-limiting enzyme for bile acids produced, which determines the content of bile acids and the ratio of CA and CDCA, respectively.
18952117 0.98 Cyp7a1 and Cyp8b1 mRNA levels were reduced in MCD-fed H-RXRalpha-null mice suggesting that the regulation of these genes is not impaired in the absence of RXRalpha.
0.97 Cyp8b1 and Cyp7a1 mRNA levels (Fig. 5).
0.95 Cyp7a1 gene expression, which catalyzes the rate-limiting step in bile acid formation from cholesterol and sterol 12alpha-hydroxylase (Cyp8b1), required for the synthesis of cholic acid.
20581237 0.98 CYP7A1/CYP8B1 pathway and increased TC spillage into the colon, where it is converted to deoxycholate (DC) by the bacterial flora and partially reabsorbed.
0.96 cholesterol 7alpha-hydroxylase (CYP7a1), sterol 27-hydroxylase (CYP27), sterol 12alpha-hydroxylase (CYP8b1) and oxysterol 7alpha-hydroxylase (CYP7b1)) were significantly different in the G4ap mice as compared with the Wt-controls (figure 5a), suggesting that the shift in bile acid composition is not due to alterations in bile acid synthesis.
0.93 Cyp7a1, Cyp8b1, Cyp27 and Cyp7b1, are similar between Wt-control and G4ap mice (n=5 in each group).
26256437 0.98 cholesterol 7alpha-hydroxylase (CYP7A1) and sterol 12alpha-hydroxylase (CYP8B1) expression, thus prohibiting BA synthesis for 48 hours after liver resection.
0.98 CYP7A1 and CYP8B1 expression.
0.87 cholesterol-7alpha-hydroxylase (CYP7A1) and sterol 12alpha-hydroxylase (CYP8B1) is converted to bile acids (BAs).
27111442 0.98 Cyp7a1 and Cyp8b1, which would theoretically lead to an increase in the production of both CA and CDCA.
0.94 Cyp8b1 expression increases concomitant with Cyp7a1 expression.
0.64 Cyp7a1 governs the BA pool size, whereas Cyp8b1 is crucial for determining the BA pool composition.
27351453 0.98 Cyp7a1 and Cyp8b1 gene transcription.
0.98 Cyp7a1 and Cyp8b1 gene transcription.
0.97 Cyp7a1 and Cyp8b1 gene transcription by two mechanisms.
30761355 0.98 CYP7A1, CYP8B1, CYP27A1, and the bile acid uptake transporter NTCP (Table 1).
0.98 CYP7A1 and CYP8B1 (Table 1).
0.97 CYP7A1, CYP8B1, and CYP27A1, but because of SHP activation by hFXR and consequent inhibition of LRH-1 and LXR, bile acids are synthesized from cholesterol.
31308634 0.98 CYP7A1 and CYP8B1 expression in the liver.
0.98 CYP7A1 and CYP8B1), decreasing bile acid synthesis.
0.90 CYP7A1 and CYP8B1 expression, which is consistent with a previous literature report.
22579755 0.98 Cyp7a1 and Cyp8b1, two important bile acid biosynthetic genes, by means of different interactions with NRs, LRH-1, HNF4alpha, and FXR.
0.98 Cyp7a1, at the Cyp8b1 promoter, GPS2 activates gene transcription by linking FXR at a distant enhancer to HNF-4 at the proximal promoter, thus mediating a long range enhancer-promoter interaction.
23880190 0.98 Cyp7a1, sterol 12alpha-hydroxylase (Cyp8b1), HMG CoA reductase (Hmgcr), and HMG CoA synthase (Hmgcs) were elevated in Asbt-/-apoE-/- versus apoE-/- mice (Fig. 3A).
0.98 Cyp7a1, and Cyp8b1.
23926955 0.98 Cyp7a1 and Cyp8b1, the classic pathway of bile acid synthesis.
0.96 Cyp7a1, Cyp8b1, and Cyp27a1, the major CYP enzymes for bile acid metabolism, was disrupted, resulting in hepatic cholestasis.
25738460 0.98 Cyp7a1 mediates the commitment step for 75% of all bile acids, thereby controlling the bile pool size, whereas Cyp8b1 activity determines the ratio of two most abundant bile acids in mouse, cholic acid (CA) and muricholic acid (MCA), thereby controlling bile pool composition (Figure 4C, bile acid pathway).
0.96 Cyp8b1, but not Cyp7a1, was significantly reduced in the livers of lncLSTR KD mice (Figures 4B and S2B).
29175453 0.98 Cyp7a1, Cyp8b1, Cyp27a1, and Cyp7b1) and transporters (Ntcp, Oatp1a1, Oatp1b2, and Mrp3).
0.97 Cyp7a1 (3-fold ), Cyp7b1 (2.5 fold ), Cyp27a1 (20% ), Cyp8b1 (120% ) and Bal (33% ).
32259714 0.98 Cyp7a1, Cyp7b1 - a cytochrome that has a minor role in the conversion of cholesterol into BAs - and Cyp8b1 that regulates the relative amount of CDCA and CA (Fig. 1a).
0.97 Cyp7a1 and Cyp8b1 via FGF19 is possibly ascribable to DSS ability to change BA metabolism and expression of related cytochromes.
21245926 0.98 CYP7A1, the knockout caused a significant drop in expression of CYP8B1, demonstrating a very strong regulatory relationship between Nr5a2 and CYP8B1 .
21354151 0.98 Cyp7a1 and Cyp8b1, the two key enzymes in bile acid synthesis , was markedly suppressed in lithogenic diet-fed PXR-/- mice (Fig. 4C).
26226008 0.98 cholesterol 7alpha hydroxylase (CYP7A1), sterol 12alpha hydroxylase (CYP8B1), sodium-taurocholate cotransporting polypeptide (NTCP), bile salt export pump (BSEP), ATP binding cassette transporter G5 (ABCG5), and ATP binding cassette transporter G8 (ABCG8), all of which are involved in the synthesis and secretion of bile acids in the liver.
29098111 0.98 CYP7A1, CYP8B1 and CYP27A1.
29692737 0.98 CYP7A1 expression levels in mice liver and significant upregulation of CYP8b1 and SHP (Figure 5A).
30464200 0.98 Cyp7a1 and Cyp8b1 compared to the control GFP-injected group (Fig. 4a,b).
24183703 0.97 Cyp7a1 and Cyp8b1) is transcriptionally suppressed by BA-mediated feedback inhibition via two mechanisms.
0.97 Cyp7a1 and Cyp8b1 are enzymes in the classic pathway for BA synthesis.
0.96 Cyp7a1, but is more important in Cyp8b1 suppression, whereas Fgf15 is important for both Cyp7a1 and 8b1 regulation.
0.93 Cyp7a1 (228%), but decreased the mRNA of Cyp8b1 (53.8%).
27895309 0.97 Cyp7a1 (C) was significantly increased in Ctnnb1CA hep mice, whereas mRNA levels of Cyp27 (D) and Cyp8b1 (E) were decreased in livers with continuous beta-catenin activation.
0.96 Cyp7a1 and down-regulation of Cyp27 and Cyp8b1 (Figure 7A-7C) as well as downregulation of Cyp2b10 (Supplementary Figure S3D).
0.94 Cyp7a1 (A) was increased in Ctnnb1TCCA hep mice, whereas mRNA levels of Cyp27 (B), Cyp8b1 (C), Fgfr4 (D) and Fxr (E) were significantly reduced.
0.92 Cyp7a1 was increased whereas Cyp27 and Cyp8b1 were reduced in Ctnnb1CA hep mice.
28181583 0.97 Cyp7a1, Cyp27a1, Cyp7b1 and Hsd3b7 are mainly expressed in somatic cells or spermatogonia; whereas Cyp8b1 showed ubiquitous expression pattern (Fig. 1c).
0.97 Cyp7a1 and Cyp8b1 were decreased whereas the one of Cyp7b1 was increased in response to BA-diet (Fig. 2d).
0.96 Cyp7a1, Cyp8b1 and a downregulation of Cyp27a1 mRNA accumulation (Fig. 2d); whereas the mRNA accumulations of Hsd3b7 and Cyp7b1 were not affected compared to Wt (Fig. 2d).
0.86 Cyp8b1 was decreased in Fxralpha-/- mice fed BA-diet whereas Cyp7a1 was increased in these mice.
30405201 0.97 Cyp7a1/Cyp27a1 classical pathway is responsible for the synthesis of BA species that protect against NAFLD while the 12-hydroxylated BA species formed via the Cyp8b1 pathway have been associated with metabolic impairments.
0.96 Cyp7a1 and Cyp39a1 were higher in females while Cyp8b1 was higher in male offspring (sex, p < 0.05) (Fig. 8A).
0.94 Cyp7a1, Cyp8b1, Cyp39a1 and Cyp27a1 in livers of offspring.
0.93 Cyp7a1, Cyp8b1 and Cyp39a1) and serum bile acid concentrations.
26701854 0.97 Cyp7a1) and sterol 12alpha-hydroxylase (Cyp8b1) on day zero.
0.97 Cyp7a1 and Cyp8b1 inhibition indicate the necessity to down-regulate BA synthesis during liver regeneration.
0.84 CYP7A1 (0-1 day) and CYP8B1 (0, 1, 2 day), but increased CYP8B1 on day 1.5 (Figure 3A).
27756364 0.97 Cyp7a1, which is the rate-limiting enzyme in the classic pathway increased 200-400 % (P = 0.001), and Cyp8b1 mRNA increased up to 100 % (P = 0.003).
0.96 Cyp7a1, the rate-limiting enzyme in the synthetic pathway (Fig. 5a), and Cyp8b1, the 12alpha-hydroxylase responsible for the synthesis of CA, as well as BA-uptake transporter Ntcp increased in livers of mice treated with the higher doses of BBR (Fig. 5c), but other genes, including the nuclear receptors and efflux transporters, were not altered (Fig. 5d).
0.92 Cyp8b1, Cyp7a1, Ntcp and FXR (in liver) were positively correlated to the increase of BBR concentrations, whereas secondary BAs and bacteria including Ruminococcus gnavus, Ruminococcus schinkii, Lactobacillus acidophilus, Lactobacillus murinus and Lactococcus lactis in terminal ileum and large intestinal contents were negatively correlated to the increase of BBR concentrations.
20041971 0.97 CYP7A1 repression by a synthetic FXR agonist, while conversely FXR repression of CYP8B1 was more dependent upon hepatic FXR expression.
0.97 CYP7A1/CYP8B1.
22912762 0.97 Cyp7a1 and Cyp8b1 are the major regulatory enzymes for the classic bile acid synthesis pathway and Cyp7b1 is used in the alternative pathway of bile acid synthesis.
0.94 cholesterol 7-alpha-hydroxylase (Cyp7a1), the rate-limiting enzyme for classic pathway of bile acid synthesis, as well as oxysterol 7-alpha-hydroxylase 1 (Cyp7b1) and sterol 12-alpha-hydroxylase (Cyp8b1), which are also involved in bile acid synthesis, were decreased in Mig-6d/d mice.
26645046 0.97 Cyp7a1 gene, and RORalpha is a positive regulator of the sterol 12alpha-hydroxylase (Cyp8b1) gene in cholic acid synthesis.
25447797 0.96 Cyp7a1 deficiency such as an elevated rate of intestinal sterol synthesis, an enhanced level of mRNA for Cyp8b1 in the liver, and depressed mRNA levels for Ibabp, Shp and Fgf15 in the distal small intestine.
0.96 Cyp7a1-deficient mice showed a decisive increase in Cyp8b1 mRNA, irrespective of whether they are fed a low (Fig. 3D) or high (Fig. 5D) cholesterol diet.
0.94 Cyp8b1 in Cyp7a1-deficient mice was induced only with CA feeding, irrespective of whether the dietary cholesterol level was high (Fig. 5D) or low.
0.88 Cyp7a1-/- mice on the low cholesterol diet containing CDCA, the rise in the mRNA level for Cyp8b1 was blunted (Fig. 3D), but this was not the case when the mutants were maintained on the high cholesterol diet (Fig. 5D).
0.79 Cyp8b1 (Fig. 3D) in the Cyp7a1+/+ mice given CDCA.
25969465 0.96 CYP8B1, an enzyme that is responsible for the synthesis of the primary bile acid cholate along the CYP7A1-initiated pathway (Vlahcevic et al.; Li-Hawkins et al.; Schwarz et al.), was even downregulated (Fig.6C).
0.96 Cyp8b1 but not of Cyp7a1 after 4-day exposures to repeated stress (Depke et al.; Konstandi et al.).
0.95 cholesterol 7alpha-hydroxylase (CYP7A1) and sterol 27-hydroxylase (CYP27A1), encoding the first enzymes of the neutral and acidic bile acid synthesis pathways, respectively, was not altered whereas that of sterol-12alpha-hydroxylase (CYP8B1) was strongly downregulated in the stressed mice (Fig.6C).
21319191 0.96 CYP8B1 and cholic acid synthesis in Cyp7a1-tg mice (1).
19835623 0.95 Cyp7a1 and Cyp8b1 were pivotal enzymes of converting cholesterol into bile acids in bile acid synthesis pathway.
0.94 (cytochrome P450 family 7 subfamily a polypeptide 1) and Cyp8b1 (cytochrome P450 family 8 subfamily b polypeptide 1) were down-regulated in B6 mice but up-regulated in D2 mice.
0.94 Cyp7a1 and Cyp8b1 decreased since the 1st week in B6 mice.
0.82 Cyp7a1 and Cyp8b1 in D2 mice.
0.78 Cyp7a1 and Cyp8b1, many other cytochrome P450 subfamily members such as Cyp2c44, Cyp2c55 and Cyp3a13 were also differently modulated.
31672964 0.95 CYP7A1 and CYP8B1 in the classical BA synthetic pathway and greatly promoted the expression of CYP27A1 and CYP7B1 in the alternative pathway.
0.94 CYP7A1 was also elevated but CYP8B1 was not significantly affected in the HFD + PTea group (Fig. 6f and Supplementary Fig. 11e).
0.88 CYP7A1 and CYP8B1 whereas the CYP7B1 was not affected compared to theabrownin group (Fig. 7g).
0.74 CYP7A1, CYP8B1, CYP27A1 and CYP7B1 with no selectivity, whereas hepatic FXR-SHP signaling selectively inhibits CYP8B1 in the classic pathway.
28166538 0.95 Cyp7a1->Hsd3b7->Cyp8b1->Cyp27a1, exhibited a spatial order that matched the position in the enzymatic cascade (Fig. 4b, c).
0.76 Cyp7a1 and Hsd3b7 were most abundant in the pericentral layer 1, the next enzyme - Cyp8b1 peaked in layers 2-3 (Fig. 4b,c, Extended Data Fig. 10f).
26795945 0.95 CYP8B1, an enzyme downstream of CYP7A1, could be involved.
23330546 0.94 CYP7A1 regulates the overall rate of bile acid synthesis, whereas CYP8B1 regulates the ratio of CA to CDCA in the bile acid pool.
0.94 CYP7A1, CYP8B1, CYP27A1 and CYP7B) are involved in hydroxylation reactions.
23240054 0.94 Cyp7a1, Cyp8b1 and Cyp27a1 encode bile acid synthetic enzymes.
31775872 0.93 Cyp8b1 expression also have significantly more CA secondary to higher CYP7A1 activity.
0.75 Cyp8b1 expression, similar to the Cyp7a1 knockout mice.
22662222 0.92 Cyp7a1, the mRNA levels for the sterol 12alpha-hydroxylase (Cyp8b1) were also induced dose-dependently (Figure 1E).
29159825 0.80 Cyp7a1 protein and Cyp8b1 mRNA expression following ethanol administration (Fig. 7A - 7B), plasma bile acid concentrations were similar in ethanol-fed AAV-M52 and AAV-GFP injected mice (Fig. 7C).
28969019 0.55 Cyp7a1, Cyp7b1, Cyp8b1 and Cyp27a1 in liver.



The preparation time of this page was 0.0 [sec].